Cabergoline .5mg per ml x 30ml
In the early 1980’s, Cabergoline was discovered by an Italian drug company Farmitalia Carlo Erba, which now Pfizer runs. Scientists discovered the drug while experimenting with ergot (fungus) alkaloids. The FDA approved the drug in 1996, and it went generic in 2005 after its patent expired in the US.
How Cabergoline works:
Cabergoline is a synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. It exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control.
In addition, receptor-binding studies indicate that Cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. In conclusion, it decreased serum prolactin levels in reserpinized rats.
Cabergoline offers use in clinical and research settings for different types of medical problems that occur when too much of the hormone prolactin is produced. Firstly, its potential benefits for use include menstrual problems, fertility and sexual problems in men and women, and increase in testosterone.
- possesses antioxidant and neuroprotective properties due to its free radical scavenging activity
Molecular Formula: C26H37N5O2
Molecular Mass: 451.6 g/mol
Chemical Name: 1-[(6-allylergolin-8ß-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea
THIS PRODUCT IS FOR RESEARCH ONLY
This designation allows the use of research chemicals and peptides strictly for in vitro testing and research, in laboratory settings only. Bodily introduction or injection of any kind, into humans or animals, is strictly illegal by law. This product is NOT for human use and can be harmful if ingested. This product is not in a sterile solution. It is not a drug, food, or cosmetic.
Please read our Terms and Conditions prior to ordering.